JP7534849B2 - セレブロンに対する小分子の親和性の測定方法 - Google Patents

セレブロンに対する小分子の親和性の測定方法 Download PDF

Info

Publication number
JP7534849B2
JP7534849B2 JP2019542183A JP2019542183A JP7534849B2 JP 7534849 B2 JP7534849 B2 JP 7534849B2 JP 2019542183 A JP2019542183 A JP 2019542183A JP 2019542183 A JP2019542183 A JP 2019542183A JP 7534849 B2 JP7534849 B2 JP 7534849B2
Authority
JP
Japan
Prior art keywords
compound
fret
crbn
complex
emission
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019542183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510632A5 (https=
JP2020510632A (ja
Inventor
ポール チャンバーレイン フィリップ
マティスキエラ マリー
カンバッタ ゴドレジ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2020510632A publication Critical patent/JP2020510632A/ja
Publication of JP2020510632A5 publication Critical patent/JP2020510632A5/ja
Priority to JP2022203130A priority Critical patent/JP2023055688A/ja
Application granted granted Critical
Publication of JP7534849B2 publication Critical patent/JP7534849B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2019542183A 2017-02-03 2018-02-02 セレブロンに対する小分子の親和性の測定方法 Active JP7534849B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022203130A JP2023055688A (ja) 2017-02-03 2022-12-20 セレブロンに対する小分子の親和性の測定方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762454654P 2017-02-03 2017-02-03
US62/454,654 2017-02-03
PCT/US2018/016609 WO2018144832A1 (en) 2017-02-03 2018-02-02 Methods for measuring small molecule affinity to cereblon

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022203130A Division JP2023055688A (ja) 2017-02-03 2022-12-20 セレブロンに対する小分子の親和性の測定方法

Publications (3)

Publication Number Publication Date
JP2020510632A JP2020510632A (ja) 2020-04-09
JP2020510632A5 JP2020510632A5 (https=) 2021-03-11
JP7534849B2 true JP7534849B2 (ja) 2024-08-15

Family

ID=63037575

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019542183A Active JP7534849B2 (ja) 2017-02-03 2018-02-02 セレブロンに対する小分子の親和性の測定方法
JP2022203130A Pending JP2023055688A (ja) 2017-02-03 2022-12-20 セレブロンに対する小分子の親和性の測定方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022203130A Pending JP2023055688A (ja) 2017-02-03 2022-12-20 セレブロンに対する小分子の親和性の測定方法

Country Status (4)

Country Link
US (2) US10816544B2 (https=)
EP (1) EP3577459A4 (https=)
JP (2) JP7534849B2 (https=)
WO (1) WO2018144832A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11963520B2 (en) 2016-01-19 2024-04-23 Celgene Corporation Transgenic mouse expressing human cereblon
WO2018144832A1 (en) 2017-02-03 2018-08-09 Celgene Corporation Methods for measuring small molecule affinity to cereblon
EP3891128A4 (en) * 2018-12-05 2022-08-17 Vividion Therapeutics, Inc. SUBSTITUTED ISOINDOLINONES AS MODULATORS OF CEREBLON-MEDIATED NEOSUBSTRATE RECRUITMENT
JP2023508891A (ja) * 2019-12-17 2023-03-06 オリオニス バイオサイエンシズ，インコーポレイテッド タンパク質の動員および／または分解のための二機能性剤
JP2023507172A (ja) * 2019-12-17 2023-02-21 オリオニス バイオサイエンシズ，インコーポレイテッド タンパク質分解の調節
EP4157888A4 (en) * 2020-05-28 2024-07-10 Cullgen (Shanghai), Inc. MODIFIED PROTEINS AND PROTEIN DEGRADATION AGENTS
EP4359404A4 (en) * 2021-06-25 2025-06-04 Celgene Corporation Cereblon-binding compounds, compositions thereof and methods of treatment therewith
JP2024143160A (ja) 2023-03-30 2024-10-11 セイコーエプソン株式会社 剛度検出装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004537047A (ja) 2001-06-14 2004-12-09 アナディーズ　ファーマスーティカルズ，アイエヌシー． 標的分子のリガンドをスクリーニングする方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE205542T1 (de) 1992-03-04 2001-09-15 Univ California Vergleichende genomhybridisierung
WO2010127980A1 (en) * 2009-05-05 2010-11-11 F. Hoffmann-La Roche Ag Fret-based binding assay
EP2436387B1 (en) 2009-05-25 2018-07-25 Celgene Corporation Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
EP2536706B1 (en) 2010-02-11 2017-06-14 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
CA2834535A1 (en) 2011-04-29 2012-11-01 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
WO2014028445A2 (en) 2012-08-14 2014-02-20 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
EP2757379A1 (en) * 2013-01-16 2014-07-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method to screen for the teratogenic potential of substances
US10272117B2 (en) 2014-02-24 2019-04-30 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
WO2015200795A1 (en) 2014-06-27 2015-12-30 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
US11963520B2 (en) 2016-01-19 2024-04-23 Celgene Corporation Transgenic mouse expressing human cereblon
WO2018144832A1 (en) 2017-02-03 2018-08-09 Celgene Corporation Methods for measuring small molecule affinity to cereblon

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004537047A (ja) 2001-06-14 2004-12-09 アナディーズ　ファーマスーティカルズ，アイエヌシー． 標的分子のリガンドをスクリーニングする方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ｊｏｕｒｎａｌ ｏｆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ，２０１６年，Ｖｏｌ．５９，ｐｐ．７７０－７７４
Ｎａｔｕｒｅ，２０１４年，Ｖｏｌ．５１２，ｐｐ．４９－５３

Also Published As

Publication number Publication date
EP3577459A1 (en) 2019-12-11
JP2023055688A (ja) 2023-04-18
WO2018144832A1 (en) 2018-08-09
JP2020510632A (ja) 2020-04-09
US20210102938A1 (en) 2021-04-08
US20180224435A1 (en) 2018-08-09
EP3577459A4 (en) 2020-12-16
US11644461B2 (en) 2023-05-09
US10816544B2 (en) 2020-10-27

Similar Documents

Publication Publication Date Title
JP7534849B2 (ja) セレブロンに対する小分子の親和性の測定方法
JP7113942B2 (ja) がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用
US11733233B2 (en) Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
US11419861B2 (en) Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
JP2019504063A5 (https=)
KR20140024914A (ko) 예측인자로 세레브론을 사용하는 암 및 염증성 질환의 치료를 위한 방법
US20180267043A1 (en) Use of biomarkers for predicting clinical sensitivity to cancer treatment
DK2972372T3 (en) Markers associated with Wnt inhibitors
JP2017533727A (ja) 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用
KR20170001962A (ko) 항 악성 종양제 조성물
CN111566483A (zh) 筛选小脑蛋白改性化合物的方法
EP2232267A1 (en) Biomarkers for monitoring the treatment by quinazolinone compounds
HK1195622A (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220425

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221220

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221220

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221228

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230110

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230210

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240531

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240802

R150 Certificate of patent or registration of utility model

Ref document number: 7534849

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150